MCC 5912 with an offshore prescription workflow gets rejected by every mainstream acquirer.
Domestic-licensed telehealth pharmacies clear US card processing. International-fulfillment pharmacies, GLP-1 compounders operating in the FDA shortage grey zone, and cross-border prescription operators do not. Stablecoin rails don't classify by prescription jurisdiction.
US card acquirers treat offshore-fulfillment pharmacy as top-tier reputational risk. Underwriting rejects the file on receipt. Domestic-only pharmacies clear; anything cross-border does not.
Compounded semaglutide and tirzepatide are legal while the FDA shortage list holds. Acquirers underwrite the risk that the shortage ends and every prescription becomes non-compliant overnight. Reserve terms reflect that.
Pharmacy chargebacks are notoriously un-representable. The evidence required (proof of delivery to prescription holder) violates HIPAA to submit. Every dispute is a loss.
- No MCC 5912 to classify — stablecoin rails carry no merchant category.
- On-chain finality removes 'I never received my order' chargeback vector.
- HIPAA-safe: no cardholder data touches the cashier.
- Weekly agent settlement supports domestic USD needs where an acquirer would have.
Questions operators in this vertical ask.
Yes, but if you're fully domestically licensed with FDA-approved medications, a normal high-risk card acquirer will likely also work. Stablecoin is highest-leverage for cross-border, compounded, or shortage-list operators the card networks won't touch.
Payment rail does not change pharmacy licensing, DEA registration, or state board obligations. The cashier provides auditable transaction records; you handle the substantive compliance.
The cashier does not receive prescription data, patient identifiers, or medical records — it only processes payments. HIPAA-covered data stays inside your pharmacy management system.
$ contact --vertical pharmacy